1. Home
  2. RIVN vs BIIB Comparison

RIVN vs BIIB Comparison

Compare RIVN & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rivian Automotive Inc.

RIVN

Rivian Automotive Inc.

HOLD

Current Price

$14.29

Market Cap

23.1B

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$177.36

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RIVN
BIIB
Founded
2009
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.1B
24.2B
IPO Year
2021
1991

Fundamental Metrics

Financial Performance
Metric
RIVN
BIIB
Price
$14.29
$177.36
Analyst Decision
Hold
Buy
Analyst Count
20
24
Target Price
$16.50
$181.77
AVG Volume (30 Days)
27.9M
1.6M
Earning Date
02-12-2026
02-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
10.97
Revenue
$5,835,000,000.00
$10,065,900,000.00
Revenue This Year
$12.15
$3.61
Revenue Next Year
$26.95
N/A
P/E Ratio
N/A
$16.32
Revenue Growth
28.21
4.77
52 Week Low
$10.36
$110.04
52 Week High
$22.69
$190.20

Technical Indicators

Market Signals
Indicator
RIVN
BIIB
Relative Strength Index (RSI) 26.10 53.90
Support Level $15.12 $170.85
Resistance Level $15.56 $176.14
Average True Range (ATR) 0.64 5.01
MACD -0.30 0.49
Stochastic Oscillator 8.20 77.13

Price Performance

Historical Comparison
RIVN
BIIB

About RIVN Rivian Automotive Inc.

Rivian is a battery electric vehicle automaker that sells its vehicles in the US and Canada. The company also develops electronic control units and related software for autos in a joint venture with Volkswagen. Rivian has multiple vehicles in its fleet, which include a luxury truck and full-size SUV and a delivery van. The company also plans to begin selling a midsize SUV in 2026. Total deliveries were nearly 52,000 in 2024. Rivian is also developing autonomous driving software to be used in its vehicles.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: